Survival outcomes from the QUAZAR AML-001 trial with oral azacitidine (Oral-AZA) for patients with acute myeloid leukemia (AML) in remission by disease subtype, cytogenetic risk, and NPM1 mutation status at diagnosis (Dx)
ONCOLOGY RESEARCH AND TREATMENT（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要